Ultragenyx Pharmaceutical Inc. (RARE)
Automate Your Wheel Strategy on RARE
With Tiblio's Option Bot, you can configure your own wheel strategy including RARE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RARE
- Rev/Share 6.197
- Book/Share 1.6076
- PB 20.2178
- Debt/Equity 5.836
- CurrentRatio 2.4546
- ROIC -0.4662
- MktCap 2993783754.0
- FreeCF/Share -4.3398
- PFCF -7.0063
- PE -5.7393
- Debt/Assets 0.6759
- DivYield 0
- ROE -2.3748
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | RARE | H.C. Wainwright | -- | Buy | -- | $80 | July 28, 2025 |
| Initiation | RARE | William Blair | -- | Outperform | -- | -- | May 28, 2025 |
News
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Great. Thank you, everyone, for joining.
Read More
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
Read More
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP Howard Horn - Executive VP of Corporate Strategy & CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Good morning, everybody.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of the company's common stock to 33 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company expects to complete BLA submission in the fourth quarter of 2025 Company expects to complete BLA submission in the fourth quarter of 2025
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025.
Read More
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Ultragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal data expected Q4 2025 could be transformative. UX111's FDA delay is manufacturing-related, not safety or efficacy; resubmission is planned, with approval possible in 2026.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
Published: July 18, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $RARE--RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Read More
Ultragenyx shares plunge after bone disorder trial misses key interim goal
Published: July 10, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) slumped around 26% on Thursday afternoon after the company and partner Mereo BioPharma said their late-stage study of setrusumab in osteogenesis imperfecta failed to meet a key interim goal. Ultragenyx is developing setrusumab as a potential first-in-class treatment for osteogenesis imperfecta, a rare genetic bone disorder with no approved therapies in the US.
Read More
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Read More
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Read More
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company's common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq …
Read More
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Read More
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.
Read More
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Read More
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
About Ultragenyx Pharmaceutical Inc. (RARE)
- IPO Date 2014-01-31
- Website https://www.ultragenyx.com
- Industry Biotechnology
- CEO Emil D. Kakkis
- Employees 1294